Weight loss technology for people with treated type 2 diabetes: a randomized controlled trial.
BACKGROUND
The prevalence of type 2 diabetes is increasing in worldwide despite the development of new treatment methods. Aim of the study was to evaluate a weight loss method on body composition, glycemic, lipid and hormone profiles, blood pressure and reactive oxygen species in people with treated type 2 diabetes.


METHODS
A 24-week open, prospective, randomized, controlled clinical trial including 272 adult patients with treated type 2 diabetes was performed. The patients were divided in two groups: Main group consisted of 208 patients who followed a method including a calorie restriction diet and optimal physical activity; Control included 64 patients who received conventional drug treatment with weight loss. Main Outcome Measures were weight loss, fasting glucose and 2-hour oral glucose tolerance test (OGTT), HbA1c. Secondary endpoints were blood pressure, lipid and insulin blood levels.


RESULTS
At 24 weeks, patients in Main weight lost between 8-18 kg (10-21%); their body mass index significantly decreased (-4.2 kg/m2) as well as their waist circumference (-13 cm) compared to Control. In Main weight loss was achieved fatty mass reduction. In Main fasting glucose and OGTT, HbA1c, blood pressure, reactive oxygen species decreased significantly, whereas hemoglobin levels and heel bone mineral density increased. In Main blood insulin levels decreased by 72.0%, cortisol levels decreased by 40.7%, while testosterone levels in men increased by 2.4 times from baseline. The application of the weight loss method led to a decrease in drug doses leading to their complete withdrawal.


CONCLUSIONS
The results of this study show the beneficial role of a weight loss method in improving glycemic, lipid and hormone profiles, electrolyte and biochemical indices, blood pressure, reactive oxygen species and bone mineral density in patients with treated type 2 diabetes.


BACKGROUND
ClinicalTrials.gov Identifier: NCT02503865. Retrospectively registered November 2015.
Metabolic Syndrome Department, Nazarbayev University Medical Center, Street Baitursynuly, 5, fl. 601, 010000 Astana, Kazakhstan.
Kuat
0000-0003-4883-295X
K
Oshakbayev
Faculty of Pathology and Forensic Medicine, Medical University Astana, Astana, Kazakhstan.
Bibazhar
B
Dukenbayeva
Faculty of Cardiology, Medical University Astana, Astana, Kazakhstan.
Gulnar
G
Togizbayeva
Department of Endocrinology, Republican Diagnostic Center at Nazarbayev University Medical Center, Astana, Kazakhstan.
Aigul
A
Durmanova
Faculty of Internal Medicine, Karaganda State Medical University, Karaganda, Kazakhstan.
Meruyert
M
Gazaliyeva
Neurodevelopmental Services, Richmond Healthcare Civic Centre, Twickenham, London UK.
Abdul
A
Sabir
Department of Endocrinology, National Scientific Cardiac Surgery Center, Astana, Kazakhstan.
Aliya
A
Issa
Department of Endocrinology, Medical University Astana, Astana, Kazakhstan.
Alisher
A
Idrisov
Glycemic/lipid and hormone profiles; Lipid/protein oxidation; Restriction diet; Type 2 diabetes; Weight loss